586 related articles for article (PubMed ID: 12747758)
1. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
[TBL] [Abstract][Full Text] [Related]
2. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.
Scott AM; Liu Z; Murone C; Johns TG; MacGregor D; Smyth FE; Lee FT; Cebon J; Davis ID; Hopkins W; Mountain AJ; Rigopoulos A; Hanai N; Old LJ
Cancer Immun; 2005 Feb; 5():3. PubMed ID: 15723450
[TBL] [Abstract][Full Text] [Related]
3. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
4. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf IG
Z Gastroenterol; 2000 Aug; 38(8):615-22. PubMed ID: 11031784
[TBL] [Abstract][Full Text] [Related]
5. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
Munn DH; Cheung NK
Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
[TBL] [Abstract][Full Text] [Related]
7. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
8. The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation.
Ericson SG; Benoit NE; Mills LE; Fanger MW
Exp Hematol; 1994 Mar; 22(3):283-9. PubMed ID: 7509291
[TBL] [Abstract][Full Text] [Related]
9. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
10. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2.
Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf I
Cytokine; 2000 Jun; 12(6):756-61. PubMed ID: 10843759
[TBL] [Abstract][Full Text] [Related]
11. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
12. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
[TBL] [Abstract][Full Text] [Related]
13. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals.
Robertson MJ; Cameron C; Lazo S; Cochran KJ; Voss SD; Ritz J
Nat Immun; 1996-1997; 15(5):213-26. PubMed ID: 9390270
[TBL] [Abstract][Full Text] [Related]
14. Interleukin (IL)-15 enhances antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells.
Nguyen QH; Roberts RL; Ank BJ; Lin SJ; Thomas EK; Stiehm ER
Cell Immunol; 1998 May; 185(2):83-92. PubMed ID: 9636686
[TBL] [Abstract][Full Text] [Related]
15. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells.
Aste-Amezaga M; D'Andrea A; Kubin M; Trinchieri G
Cell Immunol; 1994 Jul; 156(2):480-92. PubMed ID: 7912999
[TBL] [Abstract][Full Text] [Related]
16. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
Caron PC; Lai LT; Scheinberg DA
Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity.
Gan X; Zhang L; Solomon GF; Bonavida B
Brain Behav Immun; 2002 Jun; 16(3):227-46. PubMed ID: 12009684
[TBL] [Abstract][Full Text] [Related]
19. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
20. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]